Plant Name: Senecio vellereus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.536E-12 | 7.700E-08 | ALOX12, ALOX15, CYP19A1, CYP2C19, CYP2C9, FASN, GAA, HSD17B10, IDH1, MAOA, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.275E-07 | 1.322E-04 | CYP19A1, CYP2C19, CYP2C9, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.878E-07 | 3.127E-04 | ALOX12, ALOX15, CYP19A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.482E-07 | 3.486E-04 | ALOX12, ALOX15, PTGS2 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.167E-07 | 5.871E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 9.167E-07 | 5.871E-04 | PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.167E-07 | 5.871E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.748E-06 | 1.460E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.748E-06 | 1.460E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.748E-06 | 1.460E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 4.736E-06 | 2.398E-03 | CYP19A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.151E-06 | 4.151E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:2000630; positive regulation of miRNA metabolic process | 9.151E-06 | 4.151E-03 | NFKB1, RELA |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.115E-05 | 4.957E-03 | CYP19A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.372E-05 | 5.857E-03 | CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0046890; regulation of lipid biosynthetic process | 1.888E-05 | 7.463E-03 | FASN, IDH1, NFKB1, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0045075; regulation of interleukin-12 biosynthetic process | 1.919E-05 | 7.463E-03 | NFKB1, RELA |
| CC | GO:0032991; macromolecular complex | GO:0033256; I-kappaB/NF-kappaB complex | 1.919E-05 | 7.463E-03 | NFKB1, RELA |
| BP | GO:0050896; response to stimulus | GO:0009750; response to fructose | 2.558E-05 | 9.440E-03 | PTGS2, XBP1 |
| BP | GO:0009987; cellular process | GO:0071316; cellular response to nicotine | 2.558E-05 | 9.440E-03 | NFKB1, RELA |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.561E-12 | 3.336E-10 | MAOA; GAA; IDH1; ALOX15; ALOX12; PTGS2; CYP2C19; CYP19A1; HSD17B10; PTGS1; CYP2C9; FASN; ALPL |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.820E-11 | 5.946E-10 | CYP2C9; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.808E-12 | 3.336E-10 | CYP2C9; MAOA; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.615E-06 | 6.406E-05 | CYP2C9; ALOX15; CYP2C19 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.303E-05 | 2.553E-04 | MAOA; RELA; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.660E-05 | 5.979E-04 | CYP2C9; MAOA; CYP2C19 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.335E-05 | 6.069E-04 | PTGS2; RELA; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 7.077E-05 | 7.706E-04 | PTGS2; RELA; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.471E-04 | 1.311E-03 | PTGS2; RELA; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.139E-05 | 7.520E-04 | CYP2C9; CYP2C19; PTGS2 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 8.936E-05 | 8.757E-04 | PTGS2; RELA; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.996E-04 | 2.447E-03 | LMNA; RELA; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.741E-04 | 2.820E-03 | XBP1; RELA; NFKB1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.019E-03 | 7.051E-03 | PTGS2; CYP19A1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.706E-03 | 7.051E-03 | MAPT; RELA; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.323E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.277E-03 | 7.051E-03 | PTGS2; PTGS1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.232E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.765E-03 | 7.051E-03 | XBP1; RELA; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.323E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.716E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.769E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 1.664E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.876E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.101E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.716E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.159E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.159E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.987E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 4.083E-03 | 1.086E-02 | RELA; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.187E-03 | 9.466E-03 | RELA; NFKB1 |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 1.987E-03 | 7.051E-03 | RELA; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.548E-03 | 1.023E-02 | RELA; NFKB1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 4.004E-03 | 1.086E-02 | RELA; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.939E-03 | 1.293E-02 | PTGS2; NFKB1; RELA |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.242E-03 | 1.086E-02 | RELA; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.277E-03 | 7.197E-03 | RELA; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.980E-03 | 9.126E-03 | RELA; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.486E-03 | 1.099E-02 | RELA; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 4.323E-03 | 1.086E-02 | RELA; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 4.323E-03 | 1.086E-02 | RELA; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.737E-03 | 1.132E-02 | RELA; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.527E-03 | 1.272E-02 | RELA; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.711E-03 | 1.272E-02 | RELA; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.711E-03 | 1.272E-02 | RELA; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 6.869E-03 | 1.453E-02 | RELA; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 8.343E-03 | 1.669E-02 | RELA; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.276E-03 | 1.486E-02 | RELA; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.970E-03 | 1.453E-02 | RELA; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.181E-02 | 2.261E-02 | RELA; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.092E-02 | 2.140E-02 | MAPT; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.219E-02 | 2.261E-02 | RELA; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.246E-02 | 2.261E-02 | RELA; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.550E-02 | 2.534E-02 | RELA; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.312E-02 | 2.303E-02 | RELA; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.339E-02 | 2.303E-02 | RELA; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.594E-02 | 2.534E-02 | RELA; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.507E-02 | 2.534E-02 | RELA; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.932E-02 | 3.005E-02 | RELA; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.182E-02 | 4.655E-02 | PTGS2; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.813E-02 | 4.177E-02 | GAA |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 3.275E-02 | 4.719E-02 | MAOA |
| hsa00020 | Citrate cycle (TCA cycle)_Homo sapiens_hsa00020 | 2.813E-02 | 4.177E-02 | IDH1 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 2.257E-02 | 3.455E-02 | MAOA |
| hsa01210 | 2-Oxocarboxylic acid metabolism_Homo sapiens_hsa01210 | 1.603E-02 | 2.534E-02 | IDH1 |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 1.603E-02 | 2.534E-02 | MAOA |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 1.322E-02 | 2.303E-02 | ALPL |
| hsa00061 | Fatty acid biosynthesis_Homo sapiens_hsa00061 | 1.228E-02 | 2.261E-02 | FASN |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Mycobacterium tuberculosis infection | A15-A19 | FASN |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| NA: NA | Gram-positive bacterial infection | NA | FASN |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; PTGS1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dramatic weight loss | R63.4 | FASN |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; PTGS1; MAOA |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; MAPT; MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | FASN |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | FASN |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | IDH1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; PTGS1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; FASN; NFKB1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |